- Home
- TGS vs AKRO Comparison
TGS vs AKRO Comparison
Compare TGS & AKRO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- TGS
- AKRO
- Stock Information
- Founded
- TGS 1992
- AKRO 2017
- Country
- TGS Argentina
- AKRO United States
- Employees
- TGS N/A
- AKRO N/A
- Industry
- TGS Natural Gas Distribution
- AKRO Biotechnology: Pharmaceutical Preparations
- Sector
- TGS Utilities
- AKRO Health Care
- Exchange
- TGS Nasdaq
- AKRO Nasdaq
- Market Cap
- TGS 4.1B
- AKRO 3.9B
- IPO Year
- TGS N/A
- AKRO 2019
- Fundamental
- Price
- TGS $26.13
- AKRO $54.58
- Analyst Decision
- TGS Strong Buy
- AKRO Strong Buy
- Analyst Count
- TGS 1
- AKRO 6
- Target Price
- TGS $40.00
- AKRO $82.50
- AVG Volume (30 Days)
- TGS 360.2K
- AKRO 1.8M
- Earning Date
- TGS 07-17-2025
- AKRO 08-08-2025
- Dividend Yield
- TGS N/A
- AKRO N/A
- EPS Growth
- TGS 247.30
- AKRO N/A
- EPS
- TGS 0.48
- AKRO N/A
- Revenue
- TGS $1,159,816,418.00
- AKRO N/A
- Revenue This Year
- TGS N/A
- AKRO N/A
- Revenue Next Year
- TGS N/A
- AKRO N/A
- P/E Ratio
- TGS $10.95
- AKRO N/A
- Revenue Growth
- TGS 16.31
- AKRO N/A
- 52 Week Low
- TGS $14.16
- AKRO $21.02
- 52 Week High
- TGS $34.37
- AKRO $58.40
- Technical
- Relative Strength Index (RSI)
- TGS 42.88
- AKRO 68.00
- Support Level
- TGS $26.63
- AKRO $53.05
- Resistance Level
- TGS $27.72
- AKRO $56.49
- Average True Range (ATR)
- TGS 1.20
- AKRO 2.44
- MACD
- TGS -0.14
- AKRO -0.26
- Stochastic Oscillator
- TGS 13.71
- AKRO 86.02
About TGS Transportadora de Gas del Sur SA TGS
Transportadora de Gas del Sur SA is a transporters of natural gas in Latin America. The company's operating segments include Natural Gas Transportation, Midstream, Telecommunications, Production and Commercialization Liquids, Other Services, and Telecommunications. It generates maximum revenue from the Production and Commercialization of the Liquids segment. Geographically, it derives the majority of its revenue from Argentina.
About AKRO Akero Therapeutics Inc.
Akero Therapeutics Inc is a clinical-stage biotechnology company focused on developing and commercializing transformative treatments for serious metabolic diseases with high unmet medical needs. Its focus is nonalcoholic steatohepatitis (MASH), or NASH, a disease without any approved therapies. The company's product candidate efruxifermin is an FGF21 analog with properties that have the potential to address the core processes underlying NASH pathogenesis.